306 related articles for article (PubMed ID: 28230570)
1. Refractory Pure Red Cell Aplasia Manifesting as Deficiency of Adenosine Deaminase 2.
Hashem H; Egler R; Dalal J
J Pediatr Hematol Oncol; 2017 Jul; 39(5):e293-e296. PubMed ID: 28230570
[TBL] [Abstract][Full Text] [Related]
2. Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2).
Lee PY; Kellner ES; Huang Y; Furutani E; Huang Z; Bainter W; Alosaimi MF; Stafstrom K; Platt CD; Stauber T; Raz S; Tirosh I; Weiss A; Jordan MB; Krupski C; Eleftheriou D; Brogan P; Sobh A; Baz Z; Lefranc G; Irani C; Kilic SS; El-Owaidy R; Lokeshwar MR; Pimpale P; Khubchandani R; Chambers EP; Chou J; Geha RS; Nigrovic PA; Zhou Q
J Allergy Clin Immunol; 2020 Jun; 145(6):1664-1672.e10. PubMed ID: 31945408
[TBL] [Abstract][Full Text] [Related]
3. A Monogenic Disease with a Variety of Phenotypes: Deficiency of Adenosine Deaminase 2.
Özen S; Batu ED; Taşkıran EZ; Özkara HA; Ünal Ş; Güleray N; Erden A; Karadağ Ö; Gümrük F; Çetin M; Sönmez HE; Bilginer Y; Ayvaz DÇ; Tezcan I
J Rheumatol; 2020 Jan; 47(1):117-125. PubMed ID: 31043544
[TBL] [Abstract][Full Text] [Related]
4. Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment.
Meyts I; Aksentijevich I
J Clin Immunol; 2018 Jul; 38(5):569-578. PubMed ID: 29951947
[TBL] [Abstract][Full Text] [Related]
5. Adenosine Deaminase Two and Immunoglobulin M Accurately Differentiate Adult Sneddon's Syndrome of Unknown Cause.
Santo GC; Baldeiras I; Guerreiro R; Ribeiro JA; Cunha R; Youngstein T; Nanthapisal S; Leitão J; Fernandes C; Caramelo F; Almeida MDR; Brás J; Santana I;
Cerebrovasc Dis; 2018; 46(5-6):257-264. PubMed ID: 30645994
[TBL] [Abstract][Full Text] [Related]
6. Deficiency of Adenosine Deaminase 2 (DADA2), an Inherited Cause of Polyarteritis Nodosa and a Mimic of Other Systemic Rheumatologic Disorders.
Hashem H; Kelly SJ; Ganson NJ; Hershfield MS
Curr Rheumatol Rep; 2017 Oct; 19(11):70. PubMed ID: 28983775
[TBL] [Abstract][Full Text] [Related]
7. Deficiency of Adenosine Deaminase Type 2: A Description of Phenotype and Genotype in Fifteen Cases.
Nanthapisal S; Murphy C; Omoyinmi E; Hong Y; Standing A; Berg S; Ekelund M; Jolles S; Harper L; Youngstein T; Gilmour K; Klein NJ; Eleftheriou D; Brogan PA
Arthritis Rheumatol; 2016 Sep; 68(9):2314-22. PubMed ID: 27059682
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation in B-cell responses and T follicular helper cell function in ADA2 deficiency patients.
Schena F; Penco F; Volpi S; Pastorino C; Caorsi R; Kalli F; Fenoglio D; Salis A; Bertoni A; Prigione I; Bocca P; Insalaco A; De Benedetti F; Antonini F; Grossi A; Signa S; Damonte G; Ceccherini I; Filaci G; Traggiai E; Gattorno M
Eur J Immunol; 2021 Jan; 51(1):206-219. PubMed ID: 32707604
[TBL] [Abstract][Full Text] [Related]
9. Extending the Clinical Phenotype of Adenosine Deaminase 2 Deficiency.
Ben-Ami T; Revel-Vilk S; Brooks R; Shaag A; Hershfield MS; Kelly SJ; Ganson NJ; Kfir-Erenfeld S; Weintraub M; Elpeleg O; Berkun Y; Stepensky P
J Pediatr; 2016 Oct; 177():316-320. PubMed ID: 27514238
[TBL] [Abstract][Full Text] [Related]
10. Detailed analysis of Japanese patients with adenosine deaminase 2 deficiency reveals characteristic elevation of type II interferon signature and STAT1 hyperactivation.
Nihira H; Izawa K; Ito M; Umebayashi H; Okano T; Kajikawa S; Nanishi E; Keino D; Murakami K; Isa-Nishitani M; Shiba T; Honda Y; Hijikata A; Yasu T; Kubota T; Hasegawa Y; Kawashima Y; Nakano N; Takada H; Ohga S; Heike T; Takita J; Ohara O; Takei S; Takahashi M; Kanegane H; Morio T; Iwaki-Egawa S; Sasahara Y; Nishikomori R; Yasumi T
J Allergy Clin Immunol; 2021 Aug; 148(2):550-562. PubMed ID: 33529688
[TBL] [Abstract][Full Text] [Related]
11. Monogenic polyarteritis: the lesson of ADA2 deficiency.
Caorsi R; Penco F; Schena F; Gattorno M
Pediatr Rheumatol Online J; 2016 Sep; 14(1):51. PubMed ID: 27609179
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation.
Skrabl-Baumgartner A; Plecko B; Schmidt WM; König N; Hershfield M; Gruber-Sedlmayr U; Lee-Kirsch MA
Pediatr Rheumatol Online J; 2017 Aug; 15(1):67. PubMed ID: 28830446
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and management of adenosine deaminase 2 deficiency children: the experience from China.
Wang W; Zhang T; Zheng W; Zhong L; Wang L; Li J; Liu Q; Dong Y; Song H
Pediatr Rheumatol Online J; 2021 Mar; 19(1):44. PubMed ID: 33757531
[TBL] [Abstract][Full Text] [Related]
14. Novel Adenosine Deaminase 2 (ADA2) Mutations Associated With Hematological Manifestations.
Albalawi R; Hanafy E; Alnafea H; Altowijiry M; Riyad S; Abufara F; Albolowi N
J Investig Med High Impact Case Rep; 2021; 9():23247096211056770. PubMed ID: 34845942
[TBL] [Abstract][Full Text] [Related]
15. Deficiency of Adenosine Deaminase 2 (DADA2): Hidden Variants, Reduced Penetrance, and Unusual Inheritance.
Schnappauf O; Zhou Q; Moura NS; Ombrello AK; Michael DG; Deuitch N; Barron K; Stone DL; Hoffmann P; Hershfield M; Applegate C; Bjornsson HT; Beck DB; Witmer PD; Sobreira N; Wohler E; Chiorini JA; Center TAG; Dalgard CL; Center NIS; Kastner DL; Aksentijevich I
J Clin Immunol; 2020 Aug; 40(6):917-926. PubMed ID: 32638197
[TBL] [Abstract][Full Text] [Related]
16. A 9.5-year-old boy with recurrent neurological manifestations and severe hypertension, treated initially for polyarteritis nodosa, was subsequently diagnosed with adenosine deaminase type 2 deficiency (DADA2) which responded to anti-TNF-α.
Sahin S; Adrovic A; Barut K; Baran S; Tahir Turanli E; Canpolat N; Kizilkilic O; Ozkaya O; Kasapcopur O
Paediatr Int Child Health; 2020 Feb; 40(1):65-68. PubMed ID: 30642227
[TBL] [Abstract][Full Text] [Related]
17. A misleading case of deficiency of adenosine deaminase 2 (DADA2): the magnifying glass of the scientific knowledge drives the tailored medicine in real life.
Maccora I; Frongia I; Azzari C; Ricci S; Cimaz R; Simonini G
Clin Exp Rheumatol; 2018; 36(6 Suppl 115):146. PubMed ID: 30148442
[No Abstract] [Full Text] [Related]
18. Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2.
Carmona-Rivera C; Khaznadar SS; Shwin KW; Irizarry-Caro JA; O'Neil LJ; Liu Y; Jacobson KA; Ombrello AK; Stone DL; Tsai WL; Kastner DL; Aksentijevich I; Kaplan MJ; Grayson PC
Blood; 2019 Jul; 134(4):395-406. PubMed ID: 31015188
[TBL] [Abstract][Full Text] [Related]
19. Importance of the determination of enzymatic activity in the diagnosis of deficiency of adenosine deaminase 2 (DADA2).
Abbasi A; Batllori M; Gil-Sáez FJ; Rodríguez-Pintó I; Antón López J; Iglesias Jímenez E
Med Clin (Barc); 2022 Sep; 159(6):283-286. PubMed ID: 35241284
[TBL] [Abstract][Full Text] [Related]
20. Atypical phenotype of an old disease or typical phenotype of a new disease: deficiency of adenosine deaminase 2.
Çakan M; Aktay-Ayaz N; Karadağ ŞG; Tahir-Turanlı E; Stafstrom K; Bainter W; Geha RS; Chou J
Turk J Pediatr; 2019; 61(3):413-417. PubMed ID: 31916720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
